• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺癌随访中的刺激试验:血浆重组人促甲状腺素(rhTSH)水平取决于体重,而非内源性刺激的促甲状腺素(TSH)值。

Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values.

作者信息

Zanotti-Fregonara Paolo, Duron Françoise, Keller Isabelle, Khoury Alexandre, Devaux Jean-Yves, Hindié Elif

机构信息

Department of Nuclear Medicine, St. Antoine Hospital, Paris, France.

出版信息

Nucl Med Commun. 2007 Apr;28(4):257-9. doi: 10.1097/MNM.0b013e32804c58c2.

DOI:10.1097/MNM.0b013e32804c58c2
PMID:17325587
Abstract

BACKGROUND

Stimulation testing in the first year following thyroid ablation has important prognostic value in thyroid cancer patients. Recombinant human TSH (rhTSH) is better tolerated than thyroid hormone withdrawal but provides only transient stimulation so that the TSH threshold of 30 mIU x l(-1) which defines adequate testing during thyroid hormone withdrawal is not appropriate for rhTSH stimulation. We looked at rhTSH levels after a standard two intramuscular injections of 0.9 mg rhTSH.

METHODS

Plasma rhTSH levels were measured 24 h after the second injection in 143 consecutive patients.

RESULTS

rhTSH levels showed large inter-patient variation (range: 44-240; mean+/-SD: 131+/-48). There was a strong inverse correlation between TSH levels and body weight (P<0.001). Levels lower than 80 mIU x l(-1) (corresponding to 1 SD below average) were recorded in 24 patients (16.8%). These patients had an average body weight of 79.7 kg, as compared to 67.9 kg for those patients with TSH levels higher than 80 mIU x l(-1). A withdrawal test in the first year after thyroid ablation was available in 64 patients. Only one patient (1.6%) had inadequate endogenous TSH stimulation, and there was no dependence of endogenous plasma TSH levels upon weight.

CONCLUSION

Contrary to endogenous stimulation, TSH levels after rhTSH injection vary with body weight. The dosage of rhTSH may need to be adapted in patients with more than 80 kg body weight.

摘要

背景

甲状腺切除术后第一年的刺激试验对甲状腺癌患者具有重要的预后价值。重组人促甲状腺激素(rhTSH)的耐受性优于甲状腺激素撤药,但仅提供短暂刺激,因此甲状腺激素撤药期间定义充分试验的30 mIU×l⁻¹的促甲状腺激素(TSH)阈值不适用于rhTSH刺激。我们观察了标准的两次肌内注射0.9 mg rhTSH后的rhTSH水平。

方法

对143例连续患者在第二次注射后24小时测量血浆rhTSH水平。

结果

rhTSH水平在患者间差异很大(范围:44 - 240;均值±标准差:131±48)。TSH水平与体重之间存在强烈的负相关(P<0.001)。24例患者(16.8%)的TSH水平低于80 mIU×l⁻¹(比平均水平低1个标准差)。这些患者的平均体重为79.7 kg,而TSH水平高于80 mIU×l⁻¹的患者平均体重为67.9 kg。64例患者在甲状腺切除术后第一年进行了撤药试验。只有1例患者(1.6%)内源性TSH刺激不足,内源性血浆TSH水平与体重无关。

结论

与内源性刺激相反,rhTSH注射后的TSH水平随体重变化。体重超过80 kg的患者可能需要调整rhTSH的剂量。

相似文献

1
Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values.甲状腺癌随访中的刺激试验:血浆重组人促甲状腺素(rhTSH)水平取决于体重,而非内源性刺激的促甲状腺素(TSH)值。
Nucl Med Commun. 2007 Apr;28(4):257-9. doi: 10.1097/MNM.0b013e32804c58c2.
2
Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.重组人促甲状腺激素可调节绝经后妇女体内I型胶原C端肽和骨碱性磷酸酶水平,但对监测分化型甲状腺癌的绝经后妇女骨保护素的产生无影响。
J Bone Miner Res. 2005 Mar;20(3):480-6. doi: 10.1359/JBMR.041126. Epub 2004 Nov 29.
3
Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.年龄会影响分化型甲状腺癌患者停用左旋甲状腺素或重组人促甲状腺素刺激后血清促甲状腺激素水平。
Biomed Pharmacother. 2007 Sep;61(8):468-71. doi: 10.1016/j.biopha.2007.04.001. Epub 2007 May 22.
4
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.重组人促甲状腺素辅助放射性碘消融及分化型甲状腺癌的治疗:综述
Endocr Relat Cancer. 2005 Mar;12(1):49-64. doi: 10.1677/erc.1.00830.
5
rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.甲状腺癌放射性碘治疗前使用重组人促甲状腺素刺激会缩短碘-131的有效半衰期。
J Nucl Med. 2003 Jul;44(7):1065-8.
6
Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.重组人促甲状腺素注射后儿童和青少年甲状腺乳头状癌患者的血清促甲状腺素(TSH)水平。
J Clin Endocrinol Metab. 2005 Dec;90(12):6553-5. doi: 10.1210/jc.2005-1550. Epub 2005 Sep 20.
7
Recombinant human thyroid-stimulating hormone (rhTSH): clinical development.重组人促甲状腺激素(rhTSH):临床开发
J Endocrinol Invest. 1999;22(11 Suppl):8-16.
8
Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.重组人促甲状腺素辅助放射性碘残留消融术的短期临床复发率与传统甲状腺激素撤药法相似。
J Nucl Med. 2008 May;49(5):764-70. doi: 10.2967/jnumed.107.049072. Epub 2008 Apr 15.
9
The role of recombinant thyroid-stimulating hormone (rhTSH) in the detection and management of well-differentiated thyroid carcinoma: a roundtable discussion.重组促甲状腺激素(rhTSH)在分化型甲状腺癌检测与管理中的作用:一次圆桌讨论
J Endocrinol Invest. 1999;22(11 Suppl):35-41.
10
Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter.
Clin Endocrinol (Oxf). 2004 Aug;61(2):163-73. doi: 10.1111/j.1365-2265.2004.02025.x.

引用本文的文献

1
Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.重组人促甲状腺激素在分化型甲状腺癌远处转移患者治疗中的潜在应用。
Endocr Pract. 2013 Jan-Feb;19(1):139-48. doi: 10.4158/EP12244.RA.
2
Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.2008 年重组人促甲状腺激素:关注甲状腺癌的管理。
Onco Targets Ther. 2009 Jan 1;1:87-101. doi: 10.2147/ott.s3480.
3
What role for recombinant human TSH in the treatment of metastatic thyroid cancer?
Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):883-5. doi: 10.1007/s00259-008-1046-0.
4
Absence of thyrotropin-induced increase in leptin levels in patients with history of differentiated thyroid carcinoma undergoing recombinant human thyrotropin testing.在接受重组人促甲状腺素检测的分化型甲状腺癌病史患者中,促甲状腺素诱导的瘦素水平升高缺失。
J Endocrinol Invest. 2008 Oct;31(10):888-92. doi: 10.1007/BF03346437.